{"id":"W3032371821","doi":"10.1200/jco.2020.38.15_suppl.tps1111","title":"CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Taxane; Internal medicine; Tolerability; Oncology; Cohort; Chemotherapy; Nivolumab; Metastatic breast cancer; Breast cancer; Cancer; Immunotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002627901,0.002120703,0.00165432,0.0008037274,0.0006636739,0.001427292,0.001647382,0.001976108,0.005698073],"category_scores_gemma":[0.001435753,0.0007614474,0.001860353,0.0007325044,0.001465913,0.001311322,0.0007669557,0.003881976,0.001644964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001251599,"about_ca_system_score_gemma":0.003066504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002273718,"about_ca_topic_score_gemma":0.004835858,"domain_scores_codex":[0.9993302,0.0003354512,0.00002550082,0.0001037926,0.00007416354,0.0001308507],"domain_scores_gemma":[0.9984353,0.0002181332,0.0002957507,0.0001129317,0.00008282877,0.0008550173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7330725,0.100944,0.01712743,0.001307913,0.002072901,0.0005931906,0.0006828442,0.00367094,0.045689,0.0007784968,0.01721995,0.07684091],"study_design_scores_gemma":[0.6921874,0.284925,0.01217992,0.00006082644,0.0006425387,0.0004736496,0.00008960088,0.001049295,0.002175716,0.0002909974,0.005871579,0.00005346911],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782755,0.003150255,0.0008134661,0.001799819,0.0003030401,0.006751153,0.00389798,0.000235842,0.004772865],"genre_scores_gemma":[0.962689,0.003153985,0.003700603,0.002797203,0.0005359642,0.01075466,0.008806825,0.0001533392,0.00740859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005698073,"threshold_uncertainty_score":0.01906198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09154226995387651,"score_gpt":0.4490843375037694,"score_spread":0.3575420675498929,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}